<?xml version='1.0' encoding='utf-8'?>
<document id="30349489"><sentence text="Pharmacokinetic Studies of Baclofen Are Not Sufficient to Establish an Optimized Dosage for Management of Alcohol Disorder."><entity charOffset="27-35" id="DDI-PubMed.30349489.s1.e0" text="Baclofen" /><entity charOffset="106-113" id="DDI-PubMed.30349489.s1.e1" text="Alcohol" /><pair ddi="false" e1="DDI-PubMed.30349489.s1.e0" e2="DDI-PubMed.30349489.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30349489.s1.e0" e2="DDI-PubMed.30349489.s1.e1" /></sentence><sentence text="Several clinical randomized trials have evaluated the interest of baclofen in patients with alcohol use disorder"><entity charOffset="66-74" id="DDI-PubMed.30349489.s2.e0" text="baclofen" /><entity charOffset="92-99" id="DDI-PubMed.30349489.s2.e1" text="alcohol" /><pair ddi="false" e1="DDI-PubMed.30349489.s2.e0" e2="DDI-PubMed.30349489.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30349489.s2.e0" e2="DDI-PubMed.30349489.s2.e1" /></sentence><sentence text=" Depending on the study design and the inclusion criteria, the results vary from enthusiastic to pessimistic" /><sentence text=" However, all researchers and practitioners agree that they observe a wide variability in the therapeutic responses" /><sentence text=" If some patients exhibit a clinical response at low doses, ~40 mg daily, others require doses higher than 300 mg" /><sentence text=" Before multiplying new other clinical trials, it is required to better understand the reason of this variability" /><sentence text=" Several mechanisms may be responsible for providing different effects with an identical daily dose" /><sentence text=" Especially, each pharmacokinetic step, absorption, distribution, metabolism, and elimination may lead to a different exposure after an identical dose" /><sentence text=" Absorption may imply a saturation process limiting the bioavailability (F) of baclofen in some patients"><entity charOffset="79-87" id="DDI-PubMed.30349489.s9.e0" text="baclofen" /></sentence><sentence text=" In such a situation, food, or drug-drug interaction can change the absorption rate of the drug modifying the maximum concentration (Cmax) and area under the curve (AUC)" /><sentence text=" Distribution and brain penetration across the blood-brain barrier may depend of a specific transporter" /><sentence text=" These transporters are subject to genetic polymorphism and drug-drug interaction" /><sentence text=" Finally, elimination may be increased by a specific secretion pathway" /><sentence text=" This review describes all available pharmacokinetic data on these different pharmacokinetics steps aiming to identify the source of variability of baclofen in patients with alcohol use disorder"><entity charOffset="148-156" id="DDI-PubMed.30349489.s14.e0" text="baclofen" /><entity charOffset="174-181" id="DDI-PubMed.30349489.s14.e1" text="alcohol" /><pair ddi="false" e1="DDI-PubMed.30349489.s14.e0" e2="DDI-PubMed.30349489.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30349489.s14.e0" e2="DDI-PubMed.30349489.s14.e1" /></sentence><sentence text="" /></document>